Drug Trial Radar · NCT02045862
A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder
Last checked: Nov 19, 2026Latest source record: Oct 31, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,829
Actual
Start
Mar 17, 2014
Primary completion
Sep 8, 2016
Study completion Sep 8, 2016
Sponsor
- Lead sponsor
- Astellas Pharma Europe B.V.Astellas (ALPMY)
- Sponsor type
- Industry
- First posted
- Jan 27, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to examine how well the combination of two medicines (solifenacin succinate and mirabegron) worked compared to each medicine alone in the treatment of bladder problems, and how safe they were for long term use.
Conditions
- Urinary Bladder Overactive
- Overactive Bladder
- Urgency Incontinence
- Urinary Bladder Diseases\Urologic Diseases
Interventions
Solifenacin succinateDrug
Participants received solifenacin 5 mg orally once a day at the same time each day.
MirabegronDrug
Participants received mirabegron 50 mg orally once a day at the same time each day.
Placebo to match solifenacinDrug
Participants received placebo to match solifenacin 5 mg orally once a day at the same time each day. This intervention was given to maintain the blind during the study.
Placebo to match mirabegronDrug
Participants received placebo to match mirabegron 50 mg orally once a day at the same time each day. This intervention was given to maintain the blind during the study.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-Emergent Adverse Events (TEAEs)Time frame: From first dose of double-blind study drug up to 30 days after last dose of double-blind study drug (up to 56 weeks)
- Change From Baseline to End of Treatment (EoT) in Mean Number of Incontinence Episodes Per 24 HoursTime frame: Baseline and Week 52
- Change From Baseline to EoT in Mean Number of Micturitions Per 24 HoursTime frame: Baseline and Week 52
Locations
251 sites in 32 countries. Site status is shown where the registry gives one.
Site US10049
Mobile, Alabama
Site US10112
Mobile, Alabama
Site US10104
Chandler, Arizona
Site US10021
Phoenix, Arizona
Site US10122
Anaheim, California
Site US10082
Hawaiian Gardens, California
Site US10132
Los Angeles, California
Site US10133
Los Angeles, California
Site US10149
Paramount, California
Site US10003
San Diego, California
Site US10106
Tarzana, California
Site US10595
Valley Village, California
Site US10053
Wheat Ridge, Colorado
Site US10060
Bradenton, Florida
Site US10097
Hialeah, Florida
Site US10148
Hialeah, Florida
Site US10153
Hialeah, Florida
Site US10091
Jupiter, Florida
Site US10150
New Port Richey, Florida
Site US10124
Orlando, Florida
Site US10134
Orlando, Florida
Site US10009
Pembroke Pines, Florida
Site US10554
Plantation, Florida
Site US10037
Alpharetta, Georgia
Site US10127
Roswell, Georgia
Site US10120
Sandy Springs, Georgia
Site US10078
Wichita, Kansas
Site US10088
Lake Charles, Louisiana
Site US10025
Shreveport, Louisiana
Site US10558
Hanover, Maryland
Site US10282
Boston, Massachusetts
Site US10114
Watertown, Massachusetts
Site US10110
Billings, Montana
Site US10154
Missoula, Montana
Site US10553
Lincoln, Nebraska
Site US10002
Englewood, New Jersey
Site US10047
Lawrenceville, New Jersey
Site US10011
Albuquerque, New Mexico
Site US10015
Albuquerque, New Mexico
Site US10026
Garden City, New York
Showing 40 of 251 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.